WHO ICTRP trial
Biomarkers of clopidogrel resistance for predicting ischemic recurrence after…
ChiCTR2500102854 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500102854 |
|---|---|
| Public title | Biomarkers of clopidogrel resistance for predicting ischemic recurrence after cerebral artery stenting: a clinical study |
| Scientific title | Clinical application study and evaluation of clopidogrel resistance-related biomarkers in predicting the recurrence of ischemic events after cerebral artery stenting |
| Primary sponsor | NanJing First Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Diagnostic test |
| Phase | 4 |
| Countries | China |
| Conditions | Ischemic Stroke Secondary to Atherosclerotic Cerebrovascular Stenosis |
| Interventions | Gold Standard:Primary Endpoints: Recurrence of stroke at 90 days and 1 year post-antiplatelet therapy. Secondary Endpoint: In-stent restenosis. Surrogate Endpoint: ADP-induced platelet aggregation rate (%). Definition of Clopidogrel… |
| Registration date | May 21, 2025 |
| Target size | Target condition:60;Difficult condition:10 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: